Antibody selection method could mean better drugs

Apr 15, 2010 By Anne Ju
The illustration shows the streamlined antibody selection strategy. From left, random mutants of Mac-1 integrins are expressed on yeast cells. The yeast cells are screened against a sample tissue that expresses receptors identical to those that Mac-1 integrins would bind to in the body. Remaining yeast cells, now expressing only active Mac-1 integrins, are exposed to fluorescently tagged antibodies. Final selection of specific antibodies is made.

(PhysOrg.com) -- Biomedical engineering researchers have made antibodies that block only specific immune cells that cause inflammation, but not the ones the body normally uses to fight infections.

Drugs that target -- associated with everything from rheumatoid arthritis to cancer -- without suppressing the entire immune system could be the payoff of new Cornell research on lab-created .

Researchers led by Moonsoo Jin, assistant professor of biomedical engineering, made antibodies that block only specific immune cells that cause inflammation, but not the ones the body normally uses to fight infections.

The research was published online March 22 in (In print April 6, Vol. 107 no. 14).

The key to the experiments are integrins, which are proteins expressed by the body's immune cells -- in this case, cells called neutrophils -- that allow the cells to travel to a cut, infection or other source of inflammation.

Integrins are receptor molecules located on the cell surface that are like velcro that can be turned on and off. When they are chemically signaled to activate, they subtly change shape, called conformation, thereby exposing binding sites allowing them to firmly attach to receptors around them. This enables the neutrophils to stick to the inside of a blood vessel and invade into the surrounding tissue to a site of inflammation or infection.

"Integrins have these amazing, very dramatic conformational changes," said graduate student Sungkwon Kang.

Inflammatory diseases like occur because the immune system has shifted into overdrive, with the body essentially attacking itself. Immune cells, which normally fight infection, flock to an area and cause painful swelling. Drugs now in clinical trials that block this immune response are indiscriminate, suppressing even those that are involved in healthy immune responses. That's why these drugs can make patients weak and susceptible to infections.

The researchers' antibodies block a specific integrin called Mac-1, but only in its active state -- that is, in its conformation that allows it to bind to and move through tissue. The new antibodies leave alone the cells with integrins in a resting state -- those that are just waiting to be needed for an . This would greatly cut down on the side effects associated with immunosuppressive drugs.

The researchers used a novel screening method that eventually isolated only these specific antibodies. They started by growing random mutations of Mac-1 integrins on the surfaces of yeast cells. They screened the yeast cells against a sample tissue that expresses receptors identical to those that Mac-1 integrins would normally bind to in the body. After an extensive washing of the remaining , they exposed them, now expressing only active Mac-1 integrins, to fluorescently tagged antibodies to discern which antibodies bound to the remaining integrins. The strategy allowed quick, error-proof examination of antibody binding.

Therapies and treatments that could result from this research are numerous, said research associate and first author Xuebo Hu. Mac-1 activation is known to cause inflammation that can lead to some cancers, for example. Also, the antibodies could be fluorescently tagged to image, for example, inflammation or metastasized tumors.

"Blocking Mac-1 or using the active Mac-1 for diagnosis or treatment of patients could be pretty significant," Kang said.

Explore further: Ultrasound enhancement provides clarity to damaged tendons, ligaments

Related Stories

Researchers discover new drug target for inflammatory disease

Sep 22, 2008

UC Davis researchers have defined a cellular process that promotes inflammation and, at the same time, found an important starting point for identifying and testing new drugs for diseases such as sepsis, rheumatoid arthritis, ...

Exhausted B cells fail to fight HIV

Jul 14, 2008

HIV tires out the cells that produce virus-fighting proteins known as antibodies, according to a human study that will be published online July 14 in the Journal of Experimental Medicine.

Recommended for you

A better way to track emerging cell therapies using MRIs

Sep 19, 2014

Cellular therapeutics – using intact cells to treat and cure disease – is a hugely promising new approach in medicine but it is hindered by the inability of doctors and scientists to effectively track the movements, destination ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

fixer
not rated yet Apr 15, 2010
I see where this is going, and there is some merit in it for people with low grade inflammation, but it doesn't target the cause of the inflammation in people with heavy involvement, and that's dangerous for people who are seriously ill.
It will be good to see the back of steroids, chemotherapy and the like as they have proved little better than useless, often (usually) just a longer and more painful death.
If this therapy does get accepted it will be interesting to see how it is applied, I doubt it will be promoted while there are still major stocks of normal painkillers and anti-inflammitory drugs.
If it sees the light of day within 5 years I will eat my keyboard.